

**Review Article****Sex assignment and Re-assignment: A pediatric endocrinologist perspective; more than three decades of experience****Nasir A. M. Al Jurayyan (MD)**

Professor and Pediatric Endocrinologist

Endocrine Division, Department of Pediatrics, College of Medicine and King Khalid University Hospital (KKUH), King Saud University Medical City, Riyadh, Saudi Arabia

**\*Corresponding author**

Nasir A.M. Al Jurayyan

Email: [njurayyan@gmail.com](mailto:njurayyan@gmail.com)

---

**Abstract:** The birth of a child with disorder in sex development (DSD) poses a major psychological impact on the family and involves a specialized and experienced multi-disciplinary team to work with the family. There has been progress in diagnosis, surgical techniques and understanding psychosocial issues related to the management. The issue of sex assignment is so complex and challenging. This review reflects a pediatric endocrinologist perspective which developed over more than thirty years of experience.**Keywords:** sex, assignment, reassignment, perspective, endocrinologist.

---

**INTRODUCTION**

Disorders of sex development (DSD), formerly termed intersex condition, atypical genitalia, or ambiguous genitalia, constitutes a complex major social and medical emergency, figures 1 and 2. It can result from so many causes, of which, congenital adrenal hyperplasia (CAH) accounts for the majority.

Several forms of congenital adrenal hyperplasia results in significant salt-loss, which if unrecognized and not appropriately treated may lead to shock [1-3]. The Lawson Wilkin Pediatric Endocrine Society (LWPES) and the European Society for Pediatric Endocrinology (ESPE) published suggested changes to the previously known nomenclature, (table 1) [4-7].

**Table 1: Revised nomenclature**

Previous	Proposed
Intersex	Disorders of sex development (DSD)
Male pseudo hermaphrodite (under virilization of an XY male, under masculinization of an XY male)	46, XY DSD
Female pseudo hermaphrodite (over virilization of an XX female, masculinization of an XX female)	46, XX DSD
True hermaphrodite	Ovotesticular DSD
XX male (XX sex reversal)	46, XX testicular DSD
XY sex reversal	46, XY complete gonadal dysgenesis

Physicians who care for a child who have DSD must understand the embryology and physiology of sexual differentiation, and appreciate the cultural, religious and psychological needs and avoid determining sex of rearing before accurate diagnosis is reached [8-9]. In this review, we will discuss the embryology and physiology of sexual differentiation, causes, diagnosis, clinical approach to ambiguous genitalia and its management.

**Embryology and physiology of sexual differentiation**

The H-Y antigen, a minor male-specific histocompatibility antigen located on the long arm of

the Y chromosome, was widely believed to be the primary testis-inducer. However, recent studies have implicated several genes on the short arm of the Y chromosome, including the gene known as sex-determining region Y (SRY), in the development of the testis and in the determination of male gender. The gene for the anti-müllerian hormone (AMH) has been elucidated, and a reliable assay for its measurement has been developed [10-15]. The gene that codes for the androgen receptor has also been identified, furthering our understanding of complete and partial androgen-resistance syndromes [16] In addition, the genetic marker that results in 5- $\alpha$ -reductase deficiency has

recently been identified, [17] and this discovery extends our understanding of the actions of testosterone and dihydro testosterone (DHT). Another important research project shows that the female pathway is not


simply a default pathway and that several genes actively regulate female development [18]. The processes of sex determination and differentiation proceed in sequence, as shown in Figure 3.



**Fig 1:** shows Ambiguous genitalia in a 46 XX patients diagnosed with congenital adrenal hyperplasia due to 21- $\alpha$ -hydroxylase deficiency. Note: The complete masculinization with normal looking hyper pigmented male genitalia, but with no palpable gonads.



**Fig 2:** Ambiguous genitalia in 46 XY patients diagnosed with congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency. Note, the pigmented short, curved phallus, central urogenital slit and separated labioscrotal testicle.



**Fig 3:** Simplified model for sexual differentiation and the development of internal and external genitalia.

Genetically, sex is determined fertilization, by the contribution of a Y or an X chromosome from the sperm; this contribution determines the differentiation of the primordial gonads. Thus, the presence or absence of a Y chromosome, with its testis-determining factor, primarily determines the course of sexual differentiation. This differentiation is visible by the 4th week of gestation; the XY karyotype is normally associated with male differentiation, and the XX karyotype is normally associated with female development. Complete female sexual differentiation occurs in the absence of the male determinant, but female differentiation is probably regulated by a

specific genetic pathway that originates on the long arm of the X chromosome.

The presence of a single Y chromosome, even in the presence of more than one X chromosome, is sufficient to cause the development of a testis. Testicular differentiation to produce functional Leydig and Sertoli cells occurs by the 7th week of gestation and is a rapid phenomenon. This rapid differentiation contrasts with the slower development of the ovaries in the 20th week of gestation. At 7<sup>th</sup> week, the Sertoli cells are actively secreting AMH and Leydig cells are secreting testosterone, and this secretion is controlled

by placental human chorionic gonadotrophin (hCG). Thereafter, the foetal pituitary gland controls testicular function in the 2<sup>nd</sup> and 3<sup>rd</sup> trimesters. Undifferentiated embryos possess two internal duct systems, müllerian (paramesonephric) ducts and wolffian (mesonephric) ducts, but the differentiation of the internal and external genitalia is essentially complete by the end of the 1st trimester. The presence of testosterone and AMH protects the genetically male foetus from inadvertent feminization [19].

Locally secreted testosterone promotes the development of the ipsilateral wolffian duct into the epididymis, vas deferens, ejaculatory duct, and seminal vesicle. Testosterone production by one testis has no effect on the wolffian duct development on the opposite side. AMH produced by the Sertoli cells causes

regression of the ipsilateral müllerian duct. Similar to the local control of the wolffian duct, müllerian duct regression is dependent on the local secretion of AMH and unaffected by AMH secretion from the contra lateral testis. [20,21] Thus, differences in the secretion of testosterone or AMH by the two gonads can result in the presence of male internal ducts on one side and female structures on the other side. As male internal duct differentiation requires high local concentrations of testosterone, a virilised female with ovaries still has normal female internal structures. Exposure of female foetuses to androgen in early gestation, before 12<sup>th</sup> week, can lead to variable degrees of virilisation (Prader’s classification), as shown in Table 2; however, labioscrotal fusion cannot be achieved after 12<sup>th</sup> week [22, 23].

**Table-2: Degree of virilisation of the external genitalia according to Prader’s classification (23)**

Classification	Characteristics
Type 1 (P-1)	Clitoral hypertrophy
Type 2 (P-2)	Clitoral hypertrophy, urethral and vaginal orifices present, but very near
Type 3 (P-3)	Clitoral hypertrophy, single urogenital orifice, posterior fusion of the labia majora
Type 4 (P-4)	Penile clitoris, perioneoscrotal hypospadias, complete fusion of the labia majora
Type 5 (P-5)	Complete masculinisation (normal-looking male genitalia) but no palpable testes

The lack of AMH, as well as insensitivity to AMH, is known to yield persistent müllerian duct syndrome. A recent study reports that males with a 46,XY karyotype can be characterized by the presence of Fallopian tubes and a uterus; the external genitalia of these XY individuals are male, and testicular function is otherwise normal [21].

Traditionally, the appearance of the external genitalia indicates the appropriate gender assignment. Male development depends on adequate testosterone secretion, peripheral metabolism of testosterone to dihydrotestosterone (DHT), and peripheral tissue response to androgens. Male external genitalia differentiate in response to DHT, which is formed in genital skin and other sensitive structures by the metabolism of testosterone by the 5- $\alpha$ -reductase enzyme. The presence of DHT induces the elongation

of the genital tubercle, fusion of the genital folds to form the penis, fusion of the labioscrotal folds to form the scrotum, and the formation of the prostate. The response of these structures to DHT requires the presence of a normal intracellular androgen receptor. The formation of the male external genitalia is complete by the end of the 1st trimester. After the 1st trimester, further development consists only of growth of the penis and the descent of the testes into the scrotum. Both of these developments depend on the levels of foetal pituitary gonadotrophin. In the normal female, the external genitalia do not differentiate into male-specific anatomy; the genital tubercle remains small and becomes the clitoris, and the genital and labioscrotal folds remain unfused to form the labia minora and labia majora, respectively [24-32].

**Table-3:Major causes of disorders of sex development (DSD) according to karyotype**

46,XX Karyotype		
46,XX DSD	<ul style="list-style-type: none"> <li>• Congenital adrenal hyperplasia (CAH)</li> </ul>	<ul style="list-style-type: none"> <li>• Enzyme deficiency                             <ul style="list-style-type: none"> <li>▪ 21<math>\alpha</math>-hydroxylase</li> <li>▪ 11<math>\beta</math>-hydroxylase</li> <li>▪ 3<math>\beta</math>-hydroxysteroid Dehydrogenase</li> </ul> </li> </ul>
	<ul style="list-style-type: none"> <li>• Ovarian/adrenal tumours (mother–child)</li> </ul>	
	<ul style="list-style-type: none"> <li>• Exposure to exogenous medication (synthetic progestin preparation)</li> </ul>	
Ovotesticular DSD		

<b>46,XY Karyotype</b>		
46,XY DSD	<ul style="list-style-type: none"> <li>Lack of synthesis of testosterone</li> </ul>	<ul style="list-style-type: none"> <li>Testicular differentiation                             <ul style="list-style-type: none"> <li>pure gonadal dysgenesis</li> <li>absence of Leydig cells or luteinising hormone receptor</li> <li>testicular regression</li> <li>gonadotrophin hormone deficiency</li> </ul> </li> <li>Enzyme deficiency in testosterone pathway                             <ul style="list-style-type: none"> <li>20,22-desmolase</li> <li>17,20-lyase</li> <li>3<math>\beta</math>-hydroxysteroid dehydrogenase</li> <li>17<math>\alpha</math>-ketoreductase</li> </ul> </li> </ul>
	<ul style="list-style-type: none"> <li>Lack of synthesis of dihydrotestosterone</li> </ul>	<ul style="list-style-type: none"> <li>5<math>\alpha</math>-reductase deficiency</li> </ul>
	<ul style="list-style-type: none"> <li>End-organ-unresponsiveness (resistance)</li> </ul>	<ul style="list-style-type: none"> <li>Partial</li> <li>Complete</li> </ul>
Ovotesticular DSD		
Multiple or local congenital anomalies		
<b>Mixed Karyotype</b>		
Ovotesticular DSD 46,XX/46,XY		
Mixed gonadal dysgenesis 45,X/46,XY		

**Major causes of disorders of sex development (DSD):**

It is important to understand the physiology and embryology of sex-determination and sexual differentiation, but it is also essential to know the different causes of DSD; these causes are shown in Table 3. Most patients are known to have either 46,XX DSD or 46,XY DSD conditions. In 46,XX DSD individuals (previously known as female-pseudo hermaphrodites), normal ovaries and internal female organs are present; however, there are variable degrees of virilisation of the external genitalia among different individuals. Congenital adrenal hyperplasia, due to a deficiency in the 21 $\alpha$ -hydroxylase enzyme or due to deficiencies in the 11 $\beta$ -hydroxylase and 3- $\beta$ -hydroxysteroid dehydrogenase enzymes, constitutes the majority of DSD cases [33-43]. Congenital adrenal hyperplasia is not an uncommon autosomal recessive condition; it is prevalent in the Arab population due to a high rate of consanguineous matings [44] Saedi-Wong et al.; [45] reported a high prevalence of consanguineous mating among the Saudi Arabian population. However, 46,XY DSD individuals (previously known as male pseudo hermaphrodites) develop normal testes but with incomplete virilisation(under-masculinised external male genitalia, due to a variety of causes.

Only a small portion of patients have genital ambiguities extensive enough to make the

determination of sex-of-rearing difficult. Ovotesticular DSD individuals (previously known as true hermaphrodites) are rare; both testicular and ovarian tissues are present in these individuals. The most common karyotypes in ovotesticular DSD cases is 46,XX, but karyotypes of 46,XY or 46,XX/46,XY can also lead to ovotesticular DSD. The appearance of the internal and external genitalia is variable in individuals with ovotesticular DSD, and the assignment of sex for ovotesticular DSD cases usually depends on the amount of functional testicular tissue. Other disorders of gonadal differentiation, such as pure or mixed-gonadal dysgenesis or testicular regression, should be considered potential causes of ambiguous genitalia, and the presence or absence of these gonadal disorders should be investigated at the time of diagnosis. The diagnosis of ambiguous genitalia can be made only by laparoscopy or by a combination of laparotomy and a histological examination of the gonads [46-48] Ambiguous genitalia in genetic males may be comprised of multiple malformation syndromes, such as Smith-Lemli-Opitz, Vater, and Meckel’s syndromes [49-50].

Thus, the presence of other morphogenic anomalies usually indicates a non-endocrine explanation for the abnormal appearance of the genitalia. Furthermore, local ano-rectal and uro-genital anomalies such as epispdius and bladder extrophy are

known to be associated with external genital ambiguity [50].

#### Diagnostic approach:

The initial assessment of a DSD patient requires a detailed maternal and family history, as well as a careful physical examination for symptoms including hyper pigmentation, signs of salt-wasting; and anal or other local or generalized dysmorphism. The initial assessment should also provide documentation of the existing external genitalia.

Proper genital examination at birth and before declaring the sex of a child is always encouraged to prevent the trauma of sex reassignment later in life. Children with ambiguous genitalia should be transferred immediately to a facility where specialized physicians are available. A multidisciplinary team consisting of a paediatric endocrinologist, paediatric surgeon, urologist, plastic surgeon, geneticist, and a psychologist or paediatric psychiatrist should collaborate in managing such a condition. The trauma associated with gender assignment is less when the sex-of-rearing is


determined by an expert as soon as possible after birth as opposed to the experience of a gender re-assignment later in life [8, 9, 47, and 51].

A logical work-up in a child with ambiguous genitalia include the following:

- chromosomal analysis
- serum chemistry including serum glucose and electrolyte
- appropriate hormonal studies, and specification
- genetic studies

#### Radiological studies:

Pelvic ultrasonography can be performed initially which allows visualization of a neonate's adrenal glands, which may be enlarged in congenital adrenal hyperplasia (CAH), however, normal adrenal glands in ultrasonography do not exclude congenital adrenal hyperplasia, when adrenal glands are enlarged in patients with CAH, they have a cribriform appearance (Figure 4).



**Fig 4: An ultrasound image of adrenal gland showing an enlarged, lobulated gland. It has a “cribriform” appearance on a newborn with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.**

Ultrasonography also helps identify mullerian structure. In a neonate, ambiguous genitalia, enlarged adrenal glands, and evidence of a uterus are virtually pathognomonic for CAH, also genitography helps determine ductal anatomy. Computed tomography (CT) and magnetic resonance imaging (MRI) are usually not indicated but may help identify internal organs. Histological analysis (laparoscopy or laparotomy) in certain case, may identify ovarian, testicular tissues, ovotestes or streak of gonads [52-46].

#### Management:

The issue should be discussed clearly and openly, and parents need to understand immediately that their child's genitalia are abnormal but can be corrected by surgery, and that the sex-of-rearing will be

either a male or female, but this decision requires reasonable time for investigation. The announcement of the baby's sex should be deferred until supportive data are available. The embryology of sexual differentiation should be reviewed at a level that allows the parents to understand the issue at hand. Also, parents should understand that virilisation is reflective of the magnitude of androgen stimulation during foetal development, and is not necessarily indicative of the most appropriate sex-of-rearing. Establishing the genetic sex (karyotype) should be the first step, coupled with determining the anatomical status of the internal organs. Further specific hormonal investigations and therapeutic trials need to be undertaken to specify the cause of the anomaly and, hence, the appropriate therapy [3, 20, 36, 47, 52, 60-63].

The current Islamic recommendations put forward by the senior Ulama Council in Saudi Arabia as well as the experiences of local medical practitioners [64, 65] yield a set of very useful general guidelines. These recommendations are translated as follows:

1. A sex-change operation (i.e., converting someone with a completely developed gender to the opposite sex) is totally prohibited, and it is even considered criminal in accordance with the Holy Quran and the Prophet's sayings.
2. Those who have both male and female organs require further investigation, and if the evidence is more suggestive of a male gender, then it is permissible to treat the individual medically (by hormones or surgery) to eliminate his ambiguity and to raise him as a male. If the evidence is suggestive of a female gender, then it is permissible to treat her medically (by hormones or surgery) to eliminate her ambiguity and to raise her as a female.
3. Physicians must explain the results of medical investigations to the child's guardians and whether the evidence indicates that the child is male or female so that guardians are well-informed.
4. Therefore, genetically female children (46,XX karyotype) with normal ovaries and internal female organs (uterus, fallopian tubes, and upper vagina), but with some variable degree of virilisation of the external genitalia, should be raised as females; this decision is not only due to the ease of reconstruction of the female genitalia [66,67] but also due to the ability of these females to have high fertility rates and to bear children later in life [68]. Any gender-reassignment surgery should generally be performed before 2 years of age, i.e., before the child develops gender-awareness. The techniques used for clitoral recession and vaginoplasty are continually improving. In contrast, a child with a sexual ambiguity and an XY chromosome creates a rather more difficult and challenging problem, not only for the child and his family but also for the medical caretaker. Although familial interactions with the young child during the first months of life are key factors in gender and sexual role-development, it is still difficult to predict the potential for penile growth in relation to future sexual function to determine if the male gender assignment will be satisfactory.

Also, it is important to understand that it is more difficult to reconstruct a penis than it is to create a vagina. The dominant role of the male gender in the Muslim community should not overrule Islamic Laws; these Laws should not be ignored, and they should be given prime consideration. There may exist a bias concerning the influence of the karyotype, such as the

perception that a child with a 46,XY genotypes should be raised as a male. Patients with complete end-organ unresponsiveness due to androgen receptor defects (referred to as androgen insensitivity syndrome or testicular feminization) lack response to testosterone and, therefore, should be raised as females. It is advisable to remove the gonads at the time of diagnosis rather than wait until puberty, to avoid the adverse effects of testosterone on the neurons and to minimize the risk of the development of gonado blastoma [3]. The availability of estrogen replacement therapy allows gender reassignment in such cases. However, the use of estrogen replacement therapy was debated recently, and it was suggested that the removal of gonads should be deferred until puberty to allow for estrogen formation, as carcinoma in situ is rare and the earliest reported case was at 14 years of age [4]. On the other hand, in cases where genetic males demonstrate any appreciable response to exogenous stimulation, a testosterone treatment of short duration might indicate the degree of masculinisation achievable at puberty and facilitate the decision to raise such an individual as a male. In cases of 5- $\alpha$ -reductase deficiency, further virilisation occurs at puberty, along with the development of a male habitus. Many of these individuals will be fertile as adults; therefore, male gender is the appropriate choice for gender assignment, and surgical reconstruction should be performed at 18 months. [2, 3, 21]. In testicular regression syndrome, gonadotrophic hormone deficiency, and other defective testosterone-synthesis pathways, a male gender should be assigned, and the appropriate medical therapy should be given.

In individuals with ovotesticular DSD (46,XX, 46,XY, or 46,XX/46,XY karyotypes), pure gonadal dysgenesis (46,XX or 46,XY karyotypes), or mixed gonadal dysgenesis (45,X/45,XY), there can be different degrees of internal and external genital formation, depending on the amount of functioning testicular tissue. The sex-of-rearing should be female in most of these cases, and all testicular tissue must be removed at the time of diagnosis because of the risk of virilisation at puberty and the higher incidence of gonadal tumours [3].

#### **Acknowledgement:**

The author would like to thank Ms. Loida M. Sese for typing the manuscript and extend his thanks and appreciation to his family members for their support.

#### **REFERENCES**

1. Saenger P; Abnormal sex differentiation. *J Pediatr.* 1984; 104(1): 1–17.
2. Rappaport R, Forest MG; Disorders of sexual differentiation. In: Bertrand J, Rappaport R, Sizomenko PC, editors. *Paediatric endocrinology: physiology, pathophysiology, and clinical aspects.* 2nd ed. London (GB): Williams and Wilkins; 1993; 447–470.

3. Couch RM; Disorders of sexual differentiations. *Medicine North America*.1987; 14: 2632–2647.
4. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. *J Pediatr Urol*. 2006; 2(3): 148–162.
5. Hughes IA, Nihoul-Fekete C, Thomas B, Cohen-Kettenis PT; Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development. *Best Pract Res ClinEndocrinolMetab*. 2007; 21(3): 351–365.
6. Hughes IA; Disorders of sex development: A new definition and classification. *Best Pract Res ClinEndocrinolMetab*. 2008; 22(1): 119–134.
7. Barthold JS; Disorder of sex differentiation: a pediatric urologist's perspective of new terminology and recommendations. *J Urol* 2011; 185: 393-400.
8. Moshiri M, Chapman T, Fechner PY, Dubinsky T, Shnorhavorian M; Evaluation and management of disorders of sex development: multi-disciplinary approach to a complex diagnosis. *Radiographic* 2012; 32: 1500-018.
9. Palmer PW, Wisniewski AB, Schaeffe TL, Mallappe D, Trygsted JB; a model of delivering multi-disciplinary care to people with 46 XY DSD. *J PediatrUro* 2013; 8: 7-16.
10. Whelsons WJ, Russell LB; The Y-chromosome as a bearer of male determining factors in the mouse. *Proc Natl AcadSci USA*. 1959; 45(4): 560–566.
11. McCarrey JR; Abbott UK. Mechanisms of genetic sex determination, gonadal sex-determination, and germ-cell development in animals. *Adv Genet*. 1979; 20: 217–290.
12. Jost A, Vigier B, Prepin J, Perchellet JP; Studies on sex differentiation in mammals. *Rec ProgHorm Res*. 1973; 29: 1–41.
13. Wachtel SS, Ohno S; The immunogenetics of sexual development. *Prog Med Genet*.1979; 3: 109–142.
14. Simpson E, Chandler P, Goulmy E, Disteché CM, Ferguson-Smith MA, Page DC; Separation of the genetic loci for the H-Y antigen and for testis determination on human Y chromosome. *Nature*. 1987; 326(6116): 876–878.
15. Capel B; Sex in the 90s: SRY and the switch to the male pathway. *Annu Rev Physiol*.1998; 60: 497–523.
16. Quigley CA, De Bellis A, Marschke KB, El-Awady MK, Wilson EM, French FS et al.; Androgen receptor defects: Historical, clinical and molecular perspectives. *Endocr Rev*.1995; 16(3): 271–321.
17. Wilson JD, Griffin JE, Russell DW; Sterol 5 $\alpha$ -reductase 2 deficiency. *Endocr Rev*.1993; 14(5): 577–594.
18. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP; Female development in mammals is regulated by Wnt-4 signalling. *Nature*. 1999; 397(6718): 405–409.
19. Josso N. Paediatric applications of anti-müllerian hormone research. 1992 Andrea Prader lecture. *Horm Res*. 1994; 43(6): 243–248.
20. Rey R, Picard JY; Embryology and endocrinology of genital development. *Baillieres Clin Endocrinol Metab*. 1998; 12(1): 17–33.
21. Saenger PH; Physiology of sexual determination and differentiation. In: Brook CGD, Hindmarsh PC, editors. *Clinical paediatric endocrinology*. 4th ed. Oxford (GB): Blackwell Scientific Publisher; 2001; 60–76.
22. Mann DR, Akinbarni MA, Gould KG, Paul K, Wallen K; Sexual maturation in male rhesus monkeys: Importance of neonatal testosterone exposure and social rank. *J Endocrinol*. 1998; 156(3): 493–501.
23. Prader A; Der Genital befundbeimpseudohermaphroditismfeminus des kongenitalenadrenogenitalen syndromes. *HelvPaedActa*. 1954; 9: 231–247.
24. Wilson JD, Griffin JE, Leshin M, George FW; Role of gonadal hormones in development of sexual phenotypes. *Hum Genet*. 1981; 58(1): 78–84.
25. Griffin KD, Wilson JD; The androgen resistance syndromes: 5 $\alpha$ -reductase deficiency, testicular feminization, and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. *The metabolic and molecular bases of inherited disease*. 6th ed. New York (US): McGraw-Hill; 1989; 1919–1944.
26. Russell DW, Wilson JD; Steroid 5-reductase: Two genes, two enzymes. *Annu Rev Biochem*. 1994; 63: 25–26.
27. McPhaul MJ, Marcelli M, Zoppi S, Griffin JE, Wilson JD. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. *J ClinEndocrinolMetab*. 1993; 76(1): 17–23.
28. Sinnecker GHG, Hiort O, Nitsche EM, Holterhus PM, Kruse K; Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. *Eur J Pediatr*. 1997; 156(1): 7–14.
29. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketeer K, Berrevoets CA, et al.; Mechanisms of androgen receptor activation and function. *J Steroid BiochemMol Biol*. 1999; 69(1–6): 307–313.
30. Holterhus PM, Wiebel J, Sinnecker GHG, Brüggewirth HT, Sippell WG, Brinkmann AO, et al.; Clinical and molecular spectrum of somatic mosaicism in androgen insensitivity syndrome. *Pediatr Res*. 1999; 46(6): 684–690.
31. Lovinger RD, Kaplan SL, Grumbach MM; Congenital hypopituitarism associated with neonatal hypoglycemia and microphallus: four cases secondary to hypothalamic hormone deficiencies. *J Pediatr*. 1975; 87(6 Pt 2): S1171–S1181.

32. Pryse-Davies J, Dewhurst CJ; The development of the ovary and uterus in the foetus, newborn and infant: A morphological and enzyme histochemical study. *J Pathol.*1971; 103(1): 5–25.
33. Al Maghribi H; Congenital adrenal hyperplasia: problems with developmental anomalies of the external genitalia and sex assignment. *Saudi J Kidney Dis Transplant* 2007; 18(3): 405-413.
34. Taha SA, Magbool GM; The pattern of intersex and gender assignment in the Eastern province of Saudi Arabia. *Saudi Med J* 1995; 16(1): 17-22.
35. Al Jurayyan NA.; Ambiguous genitalia: two decades of experience. *Ann Saudi Med* 2011; 31(3): 284-288.
36. Al Jurayyan NAM; Disorders of sex development: diagnostic approaches and management options. An Islamic perspective. *Malaysian J Med Sci* 2011; 18(3): 4-12.
37. Anhalt H, Neely EK, Hintz RL; Ambiguous genitalia. *Pediatr Review* 1996; 17(16): 213-220.
38. Chi C, Lee HC, Neely EK.; Ambiguous genitalia in the newborn. *Neoreviews* 2008; 9(2): e78-e84.
39. Al Jurayyan NAM, Al Issa SDA, Al Nemri AM, al Otaibi HM, Babiker AMI; The spectrum of 46 XY disorders of sex development in a university centre in Saudi Arabia. *J Pediatr Endocrinol Metab* 2015; in press.
40. Abdullah MA, Katugampola M, al-Habib S, al-Jurayyan N, al-Samarrai A, al-Nuaim A, *et al.*; Ambiguous genitalia: Medical, socio-cultural and religious factors affecting management in Saudi Arabia. *Ann Trop Paediatr.* 1991; 11(4):343–348.
41. Salman H, Abanamy A, Ghassan B, Khalil M; Congenital adrenal hyperplasia. *Ann Saudi Med.* 1991; 11(1): 9–14.
42. Lubani MM, Isaa ARA, Bushnag R, al-Saleh QA, Dudin KI, Reavey PC, *et al.*; Prevalence of congenital adrenal hyperplasia in Kuwait. *Eur J Pediatr.* 1990; 149(6): 391–392.
43. Al-Jurayyan NAM, Al-Herbish AS, Abo Bakr AM, Al-Rabeeah AA, Al-Samarrai AI, Jawad AJ, *et al.*; Congenital adrenal hyperplasia in a referral hospital in Saudi Arabia: Epidemiology, pattern and clinical presentation. *Ann Saudi Med.* 1995; 15(5): 447–450.
44. Al Jurayyan NA, Osman H. The increased prevalence of congenital adrenal hyperplasia in Saudi Arabia: the role of consanguinity and multiple siblings involvement. *Eur J Res Med Sci* 2015; 3(11): 31-34.
45. Saedi-Wong S, Al-Frayh AR, Wong HYM; Socio-economic epidemiology of consanguineous matings in Saudi Arabian population. *J Asian Afr Stu.* 1989; 24: 247–52.
46. Van Niekerk WA. True hermaphroditism. In: Josso N, editor. *The intersex child.* London (GB): Karger; 1981; 80–99.
47. Pagon RA; Diagnostic approach to the newborn with ambiguous genitalia. *Pediatr Clin N Am.* 1987; 34(4): 1019–1031.
48. Jini M, Sen S, Chacko J, Zachariah N, Raghurpathy P, Mammen KE; Gender assignment in male pseudo hermaphroditism: An Indian prospective. *Pediatr Surg Int.*1993; 8(6): 500–501.
49. Dincsoy MY, Salih MAM, al-Jurayyan N, al Saadi M, Patel PJ; Multiple congenital malformations in two sibs reminiscent of hydrolethalus and pseudotrisonomy 13 syndromes, new syndromes. *Am J Med Genetics.* 1995; 56(3): 317–21.
50. Verloes A, Ayme S, Gambarelli D, Gonzales M, Le Merrer M, Mulliez N, *et al.*; Holoprosencephaly-polydactyly ('pseudotrisonomy 13') syndrome: A syndrome with features of hydrolethalus and Smith–Lemli–Opits syndromes. A collaborative multi-center study. *J Med Genet.* 1991; 28(5): 297–303.
51. Ogilvy-Stuart AL, Brain CE; Early assessment of ambiguous genitalia. *Arch Dis Child* 2004; 89: 401-407.
52. Al Jurayyan NA; Imaging of disorders of sex development. *Ann Saudi Med* 2013; 33(4): 363-7.
53. Al Jurayyan NA, Al Jurayyan RN, Mohamed SH, Babiker AM, Al Otaibi HM. Radiological imaging of disorders of sex development (DSD). *Sud J Pediatr* 2013; 13(2): 10-16.
54. Al Jurayyan NA, Patel PJ, Al Herbish AS, Abdullah MA, Abo Bakr AM, Al Rabeeah AA; Ambiguous genitalia; comparative role of pelvic ultrasonography and genitography. *Ann Trop Pediatr* 1995; 15(3): 203-207.
55. Al Alwan I, Navarro O, Danemann N, Daneman A. Clinical utility of adrenal ultrasonography in the diagnosis of congenital adrenal hyperplasia. *J Pediatr* 1999; 135: 71-75.
56. Al Jurayyan NA, Al Jurayyan RN, Al Haboob AN, Al Harbi S, Al Kabyes MA, Al Bader FB, Al Boukai AA. Radiologic imaging in patients with 46 XY disorders of sex development (DSD). A 25 years' experience form a major teaching hospital. *SJAMS* 2014 ;( CB): 2063-67.
57. Biswas K, Kapoor A, Karak A, Kriplani A, gupta DK, Kucheria K, *et al.*; Imaging intersex disorders. *J PediatrEndocrinolMetab* 2004; 17(6): 841-845.
58. Secat E, Hricak H, Gooding CA, Ho VW, Gorczyca PF, Ringertz H, *et al.* Role of MRI in the evaluation of ambiguous genitalia. *PediatrRadiol* 1994; 24: 231-35.
59. Wright NB, Smith C, Rickwood AM, Carty HM; Imaging children with ambiguous genitalia and intersex state. *ClinRadiol* 1995; 50: 823-28.
60. Biswas K, Kapoor A, Karak AK, Kriplani A, Gupta DK, Kucheria K, *et al.*; Imaging in intersex disorders. *J Pediatr Endo Met.* 2004; 17(6): 841–845.
61. Al Jurayyan NA, Al Jurayyan AN, Babiker AM, Al Otaibi HM, Al Nemri AM, Al Herbish AS *et al.*; Androgen insensitivity syndrome: an experience from a tertiary centre, Saudi Arabia. *SJAMS.* 2014; 2(GE): 215-18.

62. Al Jurayyan NA, Al Jurayyan AN, Al Issa SDA, Mohamed S, Al Otaibi HM, Babiker AM *et al.*; 5- $\alpha$ -reductase deficiency from a referral hospital, Riyadh, Saudi Arabia. *Pediatr Neonatal Care* 2015; 3: 1.
63. Rimoin DL, Schimke RN; Genetic disorders of the endocrine glands. St Louis (US): C.V. Mosby Co.; 1971.
64. Al Herbish AS, Al Jurayyan NA, Abo Bakr AM, Abdullah MA, Al Hussain M, Al Rabeah AA, *et al.*; Sex-reassignment: A challenging problem - Current medical and Islamic guidelines. *Ann Saudi Med.* 1996; 16(1): 12–15.
65. Consensus statement on intersex issues: No 176. Saudi Arabia: The Senior Ulama Council; 1992.
66. Dukett JW, Baskin LS. Genitoplasty for intersex anomalies. *Eur J Pediatr.* 1993; 152(Suppl 2): S580–S584.
67. Coran AG, Polley TZ, Jr. Surgical management of ambiguous genitalia in the infant and child. *J Pediatr Surg* 1991; 26(7): 812-820.
68. Mulaikal RM, Migeon CJ, Rock JA; fertilizing rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *N Eng J Med.* 1987; 316: 178–8.